Adia Nutrition wins IRB approval for chronic kidney disease stem cell trial

ADIA NUTRITION INC

ADIA NUTRITION INC

ADIA

0.00
  • Adia Nutrition secured IRB clearance for its chronic kidney disease stem cell study, clearing the trial to move into recruitment.
  • Study was submitted to ClinicalTrials.gov, targeting adults with Stage 2-4 CKD to evaluate safety and track kidney function and inflammation markers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.